242 related articles for article (PubMed ID: 30496374)
41. Novel Sodium/Iodide Symporter Compound Heterozygous Pathogenic Variants Causing Dyshormonogenic Congenital Hypothyroidism.
Martín M; Bernal Barquero CE; Geysels RC; Papendieck P; Peyret V; Masini-Repiso AM; Chiesa AE; Nicola JP
Thyroid; 2019 Jul; 29(7):1023-1026. PubMed ID: 31115276
[TBL] [Abstract][Full Text] [Related]
42. The oncogene BRAF V600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+/I- targeting to the membrane.
Riesco-Eizaguirre G; Gutiérrez-Martínez P; García-Cabezas MA; Nistal M; Santisteban P
Endocr Relat Cancer; 2006 Mar; 13(1):257-69. PubMed ID: 16601293
[TBL] [Abstract][Full Text] [Related]
43. A transporter gene (sodium iodide symporter) for dual purposes in gene therapy: imaging and therapy.
Cho JY
Curr Gene Ther; 2002 Dec; 2(4):393-402. PubMed ID: 12477251
[TBL] [Abstract][Full Text] [Related]
44. Iodide kinetics and experimental (131)I therapy in a xenotransplanted human sodium-iodide symporter-transfected human follicular thyroid carcinoma cell line.
Smit JW; Schröder-van der Elst JP; Karperien M; Que I; Stokkel M; van der Heide D; Romijn JA
J Clin Endocrinol Metab; 2002 Mar; 87(3):1247-53. PubMed ID: 11889195
[TBL] [Abstract][Full Text] [Related]
45. Post-transcriptional regulation of the sodium/iodide symporter by thyrotropin.
Riedel C; Levy O; Carrasco N
J Biol Chem; 2001 Jun; 276(24):21458-63. PubMed ID: 11290744
[TBL] [Abstract][Full Text] [Related]
46. Conserved charged amino acid residues in the extracellular region of sodium/iodide symporter are critical for iodide transport activity.
Li CC; Ho TY; Kao CH; Wu SL; Liang JA; Hsiang CY
J Biomed Sci; 2010 Nov; 17(1):89. PubMed ID: 21092238
[TBL] [Abstract][Full Text] [Related]
47. The porcine sodium/iodide symporter gene exhibits an uncommon expression pattern related to the use of alternative splice sites not present in the human or murine species.
Selmi-Ruby S; Watrin C; Trouttet-Masson S; Bernier-Valentin F; Flachon V; Munari-Silem Y; Rousset B
Endocrinology; 2003 Mar; 144(3):1074-85. PubMed ID: 12586784
[TBL] [Abstract][Full Text] [Related]
48. Rapid communication: predominant intracellular overexpression of the Na(+)/I(-) symporter (NIS) in a large sampling of thyroid cancer cases.
Dohán O; Baloch Z; Bánrévi Z; Livolsi V; Carrasco N
J Clin Endocrinol Metab; 2001 Jun; 86(6):2697-700. PubMed ID: 11397873
[TBL] [Abstract][Full Text] [Related]
49. Structural insights into the mechanism of the sodium/iodide symporter.
Ravera S; Nicola JP; Salazar-De Simone G; Sigworth FJ; Karakas E; Amzel LM; Bianchet MA; Carrasco N
Nature; 2022 Dec; 612(7941):795-801. PubMed ID: 36517601
[TBL] [Abstract][Full Text] [Related]
50. The sodium iodide symporter: its pathophysiological and therapeutic implications.
Spitzweg C; Morris JC
Clin Endocrinol (Oxf); 2002 Nov; 57(5):559-74. PubMed ID: 12390328
[TBL] [Abstract][Full Text] [Related]
51. Sodium iodide symporter: its role in nuclear medicine.
Chung JK
J Nucl Med; 2002 Sep; 43(9):1188-200. PubMed ID: 12215558
[TBL] [Abstract][Full Text] [Related]
52. Dietary I(-) absorption: expression and regulation of the Na(+)/I(-) symporter in the intestine.
Nicola JP; Carrasco N; Masini-Repiso AM
Vitam Horm; 2015; 98():1-31. PubMed ID: 25817864
[TBL] [Abstract][Full Text] [Related]
53. Mitogen-activated protein kinase signaling enhances sodium iodide symporter function and efficacy of radioiodide therapy in nonthyroidal cancer cells.
Jung KH; Paik JY; Ko BH; Lee KH
J Nucl Med; 2008 Dec; 49(12):1966-72. PubMed ID: 18997042
[TBL] [Abstract][Full Text] [Related]
54. MEK signaling modulates sodium iodide symporter at multiple levels and in a paradoxical manner.
Vadysirisack DD; Venkateswaran A; Zhang Z; Jhiang SM
Endocr Relat Cancer; 2007 Jun; 14(2):421-32. PubMed ID: 17639055
[TBL] [Abstract][Full Text] [Related]
55. The BRAFV600E oncogene induces transforming growth factor beta secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer.
Riesco-Eizaguirre G; Rodríguez I; De la Vieja A; Costamagna E; Carrasco N; Nistal M; Santisteban P
Cancer Res; 2009 Nov; 69(21):8317-25. PubMed ID: 19861538
[TBL] [Abstract][Full Text] [Related]
56. The Na+/I- symporter mediates iodide uptake in breast cancer metastases and can be selectively down-regulated in the thyroid.
Wapnir IL; Goris M; Yudd A; Dohan O; Adelman D; Nowels K; Carrasco N
Clin Cancer Res; 2004 Jul; 10(13):4294-302. PubMed ID: 15240514
[TBL] [Abstract][Full Text] [Related]
57. Sodium-iodide symporter and its related solute carriers in thyroid cancer.
Gong Z; Wei M; Vlantis AC; Chan JYK; Van Hasselt CA; Li D; Zeng X; Xue L; Tong MCF; Chen GG
J Endocrinol; 2024 Apr; 261(1):. PubMed ID: 38329368
[TBL] [Abstract][Full Text] [Related]
58. Lack of correlation for sodium iodide symporter mRNA and protein expression and analysis of sodium iodide symporter promoter methylation in benign cold thyroid nodules.
Neumann S; Schuchardt K; Reske A; Reske A; Emmrich P; Paschke R
Thyroid; 2004 Feb; 14(2):99-111. PubMed ID: 15068624
[TBL] [Abstract][Full Text] [Related]
59. Mechanism of anion selectivity and stoichiometry of the Na+/I- symporter (NIS).
Paroder-Belenitsky M; Maestas MJ; Dohán O; Nicola JP; Reyna-Neyra A; Follenzi A; Dadachova E; Eskandari S; Amzel LM; Carrasco N
Proc Natl Acad Sci U S A; 2011 Nov; 108(44):17933-8. PubMed ID: 22011571
[TBL] [Abstract][Full Text] [Related]
60. Cell surface targeting accounts for the difference in iodide uptake activity between human Na+/I- symporter and rat Na+/I- symporter.
Zhang Z; Liu YY; Jhiang SM
J Clin Endocrinol Metab; 2005 Nov; 90(11):6131-40. PubMed ID: 16105966
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
